Objective:To investigate the effects of Yiqi Huoxue Tongguan Decoction on hemorheology, electrocardiogram, and peripheral blood expression of microRNA-155 and vasodilator-stimulated phosphoprotein (VASP) in patients with coronary heart disease and angina. Methods:A total of 102 patients with coronary heart disease and angina who were diagnosed and treated at the Department of Cardiology, Hangzhou Hospital of Traditional Chinese Medicine from May 2023 to May 2024 were prospectively selected and randomly assigned into two groups using the envelope method. The control group ( n = 51) received conventional treatment, while the observation group ( n = 51) received Yiqi Huoxue Tongguan Decoction in addition to conventional treatment. The therapeutic effects of both groups were compared 4 weeks after treatment. Results:After treatment, the observation group showed significantly higher values for left ventricular ejection fraction [(57.48 ± 4.83)%], VASP [(385.95 ± 87.44) ng/L], and stroke volume [(78.96 ± 4.77) mL] compared with the control group [(52.22 ± 4.26)%, (339.85 ± 84.47) ng/L, (73.89 ± 5.14) mL, t = 5.83, 2.71, 5.16, all P < 0.05]. In addition, the observation group had significantly lower values for platelet aggregation rate [(32.32 ± 6.82)%], microRNA-155 (0.24 ± 0.05), plasma viscosity [(1.32 ± 0.29) mPa·s], whole blood high shear viscosity [(4.11 ± 0.77) mPa·s], interleukin-6 [(16.45 ± 3.81) μg/L], fibrinogen [(3.12 ± 0.77) g/L], high-sensitivity C-reactive protein [(9.85 ± 2.15) mg/L], and left ventricular end-systolic diameter [(36.25 ± 3.59) mm] compared with the control group ( t = 5.90, 4.86, 3.64, 3.31, 9.58, 3.95, 7.25, 6.23, all P < 0.05). The observation group also had a lower traditional Chinese medicine syndrome score [(9.52 ± 1.04) points], fewer angina attacks per week [(3.24 ± 0.71) times/week], and shorter attack duration [(2.54 ± 1.06) min/attack] compared with the control group [(12.76 ± 1.55) points, (4.56 ± 0.94) times/week, (4.26 ± 1.14) min/attack, t = 12.40, 0.20, 7.89, all P < 0.001]. The observation group showed significantly better electrocardiogram outcomes than the control group ( Z = 2.76, P = 0.006). Conclusions:Yiqi Huoxue Tongguan Decoction for the treatment of coronary heart disease and angina can regulate the expression of inflammatory factors, microRNA-155, and VASP, improve hemorheology and cardiac function, and reduce the frequency of angina attacks.

Objective:To investigate the effects of Yiqi Huoxue Tongguan Decoction on hemorheology, electrocardiogram, and peripheral blood expression of microRNA-155 and vasodilator-stimulated phosphoprotein (VASP) in patients with coronary heart disease and angina. Methods:A total of 102 patients with coronary heart disease and angina who were diagnosed and treated at the Department of Cardiology, Hangzhou Hospital of Traditional Chinese Medicine from May 2023 to May 2024 were prospectively selected and randomly assigned into two groups using the envelope method. The control group ( n = 51) received conventional treatment, while the observation group ( n = 51) received Yiqi Huoxue Tongguan Decoction in addition to conventional treatment. The therapeutic effects of both groups were compared 4 weeks after treatment. Results:After treatment, the observation group showed significantly higher values for left ventricular ejection fraction [(57.48 ± 4.83)%], VASP [(385.95 ± 87.44) ng/L], and stroke volume [(78.96 ± 4.77) mL] compared with the control group [(52.22 ± 4.26)%, (339.85 ± 84.47) ng/L, (73.89 ± 5.14) mL, t = 5.83, 2.71, 5.16, all P < 0.05]. In addition, the observation group had significantly lower values for platelet aggregation rate [(32.32 ± 6.82)%], microRNA-155 (0.24 ± 0.05), plasma viscosity [(1.32 ± 0.29) mPa·s], whole blood high shear viscosity [(4.11 ± 0.77) mPa·s], interleukin-6 [(16.45 ± 3.81) μg/L], fibrinogen [(3.12 ± 0.77) g/L], high-sensitivity C-reactive protein [(9.85 ± 2.15) mg/L], and left ventricular end-systolic diameter [(36.25 ± 3.59) mm] compared with the control group ( t = 5.90, 4.86, 3.64, 3.31, 9.58, 3.95, 7.25, 6.23, all P < 0.05). The observation group also had a lower traditional Chinese medicine syndrome score [(9.52 ± 1.04) points], fewer angina attacks per week [(3.24 ± 0.71) times/week], and shorter attack duration [(2.54 ± 1.06) min/attack] compared with the control group [(12.76 ± 1.55) points, (4.56 ± 0.94) times/week, (4.26 ± 1.14) min/attack, t = 12.40, 0.20, 7.89, all P < 0.001]. The observation group showed significantly better electrocardiogram outcomes than the control group ( Z = 2.76, P = 0.006). Conclusions:Yiqi Huoxue Tongguan Decoction for the treatment of coronary heart disease and angina can regulate the expression of inflammatory factors, microRNA-155, and VASP, improve hemorheology and cardiac function, and reduce the frequency of angina attacks.